Jane Street Group LLC Has $3.75 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Jane Street Group LLC decreased its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 45.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 189,452 shares of the company's stock after selling 155,640 shares during the period. Jane Street Group LLC owned about 0.26% of Kiniksa Pharmaceuticals worth $3,747,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $158,000. Tower Research Capital LLC TRC increased its position in shares of Kiniksa Pharmaceuticals by 117.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after purchasing an additional 4,575 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after purchasing an additional 1,004 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after buying an additional 719 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth $258,000. Institutional investors own 53.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on KNSA shares. Citigroup began coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective on the stock. Wedbush reissued an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Finally, Jefferies Financial Group raised their price objective on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $26.84 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The firm has a market capitalization of $1.95 billion, a PE ratio of -191.70 and a beta of 0.07. The company's 50-day moving average is $22.51 and its 200-day moving average is $21.29.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm's revenue for the quarter was up 72.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.25) earnings per share. As a group, analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Activity

In related news, insider Ross Moat sold 18,259 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the completion of the sale, the insider now directly owns 9,415 shares in the company, valued at approximately $191,030.35. The trade was a 65.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Michael R. Megna sold 9,051 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the sale, the chief accounting officer now owns 26,528 shares in the company, valued at $595,553.60. The trade was a 25.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 228,768 shares of company stock valued at $5,591,506. 54.57% of the stock is owned by company insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.